Abstract: A biopharmaceutical agent including a 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) and/or a fragment thereof for use in treatment and/or prevention of atherosclerosis and/or obesity and/or insulin resistance and/or diabetes. The biopharmaceutical agent may be encapsulated by functionalized or non-functionalized nanoparticles, and further may be formulated to include a carrier to provide a pharmaceutical composition for parental or non-parental administration. In use, the biopharmaceutical agent reduces lipid content in target cells. Also, a method of decreasing lipid concentration in a target cell of a human or animal subject.

Abstract: A wearable motion-signaling bag is provided. The bag includes a housing, one or more straps connected to the housing and shaped to be worn by a user; one or more motion sensors; one or more lights contacting at least one surface of the housing; one or more controls configured to be activated by the user; and a microcontroller operable to execute under programmable control and interfaced to one or more of the sensors, the controls, and the lights, the microcontroller configured to provide signals regarding the motion of the user through the lights based on sensed data from the motion sensors and commands from the capacitive controls. The bag can receive commands from a user device and provide the signals based on the commands.